New study reduces risks associated with switching MS medication
A best treatment pathway has been identified for people with multiple sclerosis (MS) whose current medication puts them at risk of a serious brain infection.
Jun 5, 2023
0
27
A best treatment pathway has been identified for people with multiple sclerosis (MS) whose current medication puts them at risk of a serious brain infection.
Jun 5, 2023
0
27
MS relapses of clinical relevance are known to occur in up to 80 percent of patients within four to seven months of stopping natalizumab. It is also a known fact that pregnancy has a mitigating effect on the disease. To find ...
Feb 4, 2022
0
11
Two new studies look at the effects of stopping the newer, stronger drug natalizumab for multiple sclerosis (MS) during pregnancy. Natalizumab is generally prescribed for people with MS who have not responded to or cannot ...
Feb 7, 2018
0
3
A commonly-prescribed multiple sclerosis (MS) infusion medication linked to a rare but serious side effect is safer to use when dosing intervals are extended, according to a new study led by MS specialists NYU Langone Health.
Feb 3, 2018
0
34
(HealthDay)—Rituximab has better efficacy and lower discontinuation rates than other disease-modifying treatment (DMT) choices for newly diagnosed relapsing-remitting multiple sclerosis (RRMS), according to a study published ...
Jan 9, 2018
0
3
People who take the drug natalizumab for multiple sclerosis may have up to a 10 times greater risk of developing a risk biomarker for activity of a virus that can lead to an often fatal brain disease, according to a study ...
Jan 27, 2016
0
1
In a study of 1,964 patients with multiple sclerosis (MS) led by researchers at the NYU Langone Multiple Sclerosis Comprehensive Care Center, extending the dose of natalizumab from 4 weeks up to 8 weeks was shown to be well-tolerated ...
Apr 20, 2015
0
9
Treatment with natalizumab in patients with multiple sclerosis (MS) appears linked with JC virus (JCV) infection, which can lead to a rare and often fatal demyelinating disease of the central nervous system called progressive ...
Mar 24, 2014
0
0
(HealthDay)—The U.S. Food and Drug Administration is investigating the possible association between a rare brain infection and the multiple sclerosis (MS) drug Gilenya (fingolimod), according to a drug safety alert issued ...
Aug 31, 2013
0
0
Amyloids—clumps of misfolded proteins found in the brains of people with Alzheimer's disease and other neurodegenerative disorders—are the quintessential bad boys of neurobiology. They're thought to muck up the seamless ...
Apr 3, 2013
1
0